VSTM Verastem, Inc.

CIK 0001526119 45 ready 8-Ks latest June 17, 2026, 8:52 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 45

Latest filing June 17, 2026, 8:52 AM ET

Top materiality 0.95

Event mix other_material ×31 · leadership ×5 · debt ×3

Sentiment 22 pos · 1 neg · 22 neu

Latest earnings reported 2025-FY

Executive change recent →

Recent 8-K filings for VSTM

Highest-materiality recent filing

FDA approves Verastem's AVMAPKI FAKZYNJA for KRAS-mutated recurrent LGSOC

May 8, 2025, 7:59 PM ET regulatory materiality 0.95 positive item 7.01 item 8.01 item 9.01

First-ever FDA-approved treatment for KRAS-mutated recurrent LGSOC; accelerated approval based on Phase 2 RAMP 201.
RAMP 201 showed 44% overall response rate (BIRC) in 57 patients; median duration of response range 3.3–31.1 months.

Read filing →

June 17, 2026, 8:52 AM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2

6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).
May 26, 2026, 8:15 AM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×5

Verastem shareholders elect three Class II directors, approve equity plans at 2026 annual meeting

Michael Bailey, Brian Stuglik, Karin Tollefson elected Class II directors; each received over 51M votes for.
May 7, 2026, 7:59 PM ET other materiality 0.15 neutral item 7.01 item 9.01

Verastem posts updated corporate presentation on RAS/MAPK pipeline; no new financial data

Corporate presentation dated May 7, 2026, furnished as Exhibit 99.1.
March 4, 2026, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Verastem posts updated corporate presentation; no specific financial or clinical data disclosed in filing

Corporate presentation dated March 4, 2026, furnished as Exhibit 99.1 to Form 8-K.
February 4, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

Verastem reports preliminary 2025 product revenue $30.9M; cash runway to H1 2027

Preliminary AVMAPKI FAKZYNJA CO-PACK net revenue: Q4 2025 ~$17.5M, full year 2025 ~$30.9M (launch from May 2025).
January 8, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027

AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.
December 31, 2025, 6:59 PM ET other material materiality 0.75 negative item 7.01 item 8.01 item 9.01

Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D

Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).
December 19, 2025, 6:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01

Verastem: new chairman, president of development appointed; COO departs; RAMP 301 enrollment complete

John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.
November 17, 2025, 6:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Verastem raises ~$96.9M in public offering of common stock and pre-funded warrants

Offering includes 8,543,794 firm shares and 3,870,000 pre-funded warrants at $7.25/share; underwriters exercised full option for 1,862,069 additional shares.
November 4, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M

AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.
October 23, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients

No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.
October 20, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025

ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.
September 8, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Verastem reports $2.1M net product revenue from AVMAPKI FAKZYNJA launch in first 6 weeks

AVMAPKI FAKZYNJA co-pack approved May 8, 2025 for KRAS-mutant recurrent LGSOC; $2.1M net revenue in first six weeks.
August 13, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D

ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.
June 2, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375

Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.
June 2, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor

FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.
May 23, 2025, 7:59 PM ET other material materiality 0.70 positive item 5.07 item 7.01 item 8.01 item 9.01

Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC

Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.
May 8, 2025, 7:59 PM ET regulatory materiality 0.95 positive item 7.01 item 8.01 item 9.01

FDA approves Verastem's AVMAPKI FAKZYNJA for KRAS-mutated recurrent LGSOC

First-ever FDA-approved treatment for KRAS-mutated recurrent LGSOC; accelerated approval based on Phase 2 RAMP 201.
April 25, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 7.01 item 9.01

Verastem raises $75M private placement for ovarian cancer drug launch and R&D

Gross proceeds of ~$75M from sale of 3.43M shares at $7.00 and 7.29M pre-funded warrants at $6.9999.
March 20, 2025, 7:59 PM ET other material materiality 0.65 neutral item 7.01 item 9.01

Verastem updates pipeline; PDUFA June 30, 2025 for avutometinib+defactinib in LGSOC

PDUFA action date June 30, 2025 for NDA of avutometinib+defactinib in KRAS mutant recurrent LGSOC; launch prep underway.
January 23, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Verastem exercises option for exclusive ex-Asia rights to KRAS G12D inhibitor VS-7375

Exercised GenFleet option on Jan 14, 2025 for VS-7375, an oral, selective KRAS G12D (ON/OFF) inhibitor.
January 21, 2025, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Verastem appoints Matthew E. Ros as COO effective Jan 14, 2025

Matthew E. Ros appointed Chief Operating Officer; reports to CEO Daniel W. Paterson.
January 13, 2025, 6:59 PM ET debt materiality 0.85 positive item 1.01 item 1.02 item 2.02 item 2.03 item 3.02 item 8.01 item 9.01

Verastem secures up to $150M from Oberland Capital, repays Oxford loan, NDA accepted with June PDUFA

Initial $75M notes issued; net proceeds~$32.3M after repaying $42.7M Oxford loan; interest-only 6 years.
October 17, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Verastem reports 31% ORR with avutometinib/defactinib in RAMP 201; NDA submission ongoing

Confirmed ORR of 31% overall (44% KRAS mutant, 17% KRAS wild type) by BICR.
July 25, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Verastem raises ~$51.1M in underwritten offering of common stock and warrants

13.3M shares of common stock and 13.3M warrants offered at $3.00 per combined unit.
July 23, 2024, 7:59 PM ET other material materiality 0.55 positive item 8.01

Verastem initiates rolling NDA for avutometinib/defactinib; RAMP 201 median duration 9 months

Rolling NDA for avutometinib+defactinib in recurrent KRAS mutant LGSOC started May 2024; priority review requested.
June 26, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Verastem initiates rolling NDA for avutometinib+defactinib in recurrent LGSOC; ORR 27%

Rolling NDA submission for avutometinib + defactinib in recurrent LGSOC started H2 2024; potential FDA approval in 2025.
May 24, 2024, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

Verastem initiates rolling NDA to FDA for avutometinib/defactinib in KRAS mutant LGSOC

Rolling submission of NDA seeking accelerated approval for recurrent KRAS mt LGSOC; initial sections include nonclinical and quality.
May 23, 2024, 7:59 PM ET other material materiality 0.65 positive item 5.07 item 7.01 item 8.01 item 9.01

Verastem reports 83% confirmed ORR in RAMP 205 dose level 1 for first-line metastatic pancreatic cancer

83% (5/6) confirmed partial response in dose level 1 cohort; dose cleared after one DLT.
April 9, 2024, 7:59 PM ET other material materiality 0.65 neutral item 7.01 item 9.01

Verastem outlines NDA filing plan for avutometinib/defactinib in LGSOC by H1 2024; cash $137.1M

Topline data from RAMP 201 trial of avutometinib + defactinib in LGSOC expected H1 2024; rolling NDA for accelerated approval to commence same period.
January 29, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

Verastem outlines 2024 priorities: NDA submission for avutometinib/defactinib in LGSOC in H1 2024

Plans to begin rolling NDA submission for accelerated approval of avutometinib/defactinib in recurrent LGSOC in H1 2024; potential commercial launch in 2025.
January 19, 2024, 6:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes

Verastem stockholders approve option exchange at special meeting

Stockholders approved one-time exchange of certain stock options held by executive officers, employees, and non-employee directors.
January 8, 2024, 6:59 PM ET debt materiality 0.30 neutral item 1.01 item 2.03 item 9.01 ◈ Material Agreements

Verastem extends Term C Loan draw deadline by one year to March 2025

Extended outside date for Term C Loan draw from March 31, 2024 to March 31, 2025.
October 27, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Verastem appoints Daniel Calkins as permanent CFO; $300K salary + 25K stock option

Daniel Calkins appointed CFO effective Oct 24, 2023, after serving as interim since Oct 31, 2022.
September 28, 2023, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC

Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.
September 12, 2023, 7:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Verastem posts corporate presentation; content not fully disclosed in filing

Corporate presentation posted on Verastem website on September 12, 2023, furnished as Exhibit 99.1.
August 4, 2023, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change

Verastem enters CEO employment agreement with Daniel Paterson; $600K salary, equity grants

Daniel Paterson appointed President & CEO effective Aug 1, 2023; employment agreement signed Aug 2, 2023.
July 12, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change ×3

Verastem Oncology CEO Stuglik retires; President Paterson appointed CEO effective Aug 1

CEO Brian Stuglik retires effective July 31, 2023; receives $421,850 cash bonus.
June 21, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Verastem raises ~$97.8M in underwritten offering of common stock and pre-funded warrants

Offering includes 7,181,409 shares at $9.75, 1,538,591 pre-funded warrants at $9.749, and underwriters' option for 1,308,000 shares exercised in full.
June 8, 2023, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing

Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.
May 31, 2023, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Verastem effects 1-for-12 reverse stock split to meet Nasdaq price requirement

Reverse stock split effective 5:00 p.m. ET May 31, 2023; trading on split-adjusted basis June 1 under VSTM.
May 25, 2023, 7:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial

Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.
May 16, 2023, 7:59 PM ET other material materiality 0.50 neutral item 5.07 ◈ Shareholder Votes ×4

Verastem shareholders approve reverse stock split ratio 1:10-30, elect three Class II directors

Elected Robert Gagnon, Brian Stuglik, and Karin Tollefson as Class II directors until 2026 annual meeting.
March 27, 2023, 7:59 PM ET debt materiality 0.50 neutral item 2.03 ◈ Debt Financings

Verastem draws $15M Term B Loan from Oxford Finance facility

Drew $15M Term B Loan on March 22, 2023, after receiving at least $50M in equity proceeds.
March 13, 2023, 7:59 PM ET other material materiality 0.50 neutral item 7.01

Verastem reports $2M deposit at Silicon Valley Bank; depositors fully protected by FDIC

Company had ~$2 million on deposit at SVB when FDIC took control.

Executive changes

Appointed

Matthew E. Ros

Chief Operating Officer

VSTM · Verastem, Inc.

Effective: 2025-01-14
Filed: January 21, 2025, 6:59 PM ET

Effective January 14, 2025, Verastem, Inc. (the “Company”) appointed Matthew E. Ros as Chief Operating Officer of the Company.

Appointed

Daniel Calkins

Chief Financial Officer

VSTM · Verastem, Inc.

Effective: 2023-10-24
Filed: October 27, 2023, 7:59 PM ET

On October 24, 2023, the board of directors (the “Board”) of Verastem, Inc. (the “Company”) appointed Daniel Calkins as Chief Financial Officer of the Company.

Appointed

Daniel Paterson

President and Chief Executive Officer

VSTM · Verastem, Inc.

Effective: 2023-08-01
Filed: August 4, 2023, 7:59 PM ET

Daniel Paterson was appointed to the position of President and Chief Executive Officer of Verastem, Inc. (the “Company”) effective as of August 1, 2023

Departed

Brian Stuglik

Chief Executive Officer

VSTM · Verastem, Inc.

Effective: 2023-07-31
Successor: Daniel Paterson
Filed: July 12, 2023, 7:59 PM ET

On July 7, 2023, Brian Stuglik notified Verastem, Inc. (the “Company)” of his decision to retire as Chief Executive Officer of the Company, effective July 31, 2023

Role change

Daniel Paterson

President and Chief Executive Officer

VSTM · Verastem, Inc.

Effective: 2023-07-31
Filed: July 12, 2023, 7:59 PM ET

Daniel Paterson, 62, the Company’s President and Chief Operating Officer, will be appointed to the position of President and Chief Executive Officer as of the Effective Date.

Appointed

Daniel Paterson

Class III director

VSTM · Verastem, Inc.

Effective: 2023-07-31
Filed: July 12, 2023, 7:59 PM ET

In connection with his appointment, Mr. Paterson will also be appointed to the Board, to serve as a Class III director.

Earnings & guidance

2025-FY EPS reported -$3.02 filing →

Materiality & sentiment trend

Max materiality 0.95 · Median 0.70 · Most common event other_material

22 positive 1 negative 22 neutral

source · VSTM on sec.gov